Barclays raised the firm’s price target on Carlyle to $56 from $55 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for the alternative asset managers. It feels like we are getting closer and closer to a “normal” market environment, but disclosures from KKR, public commentary, and other market data suggest a slower Q1, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CG:
- Carlyle weighing strategic options for StandardAero, Reuters reports
- Carlyle Group Board Evolution with Afsaneh Beschloss’s Arrival
- Teva, Launch Therapeutics enter clinical collaboration agreement
- Carlyle Group Announces COO Transition and Strategic Leadership Update
- Carlyle COO Christopher Finn to retire, Lindsay LoBue to succeed as COO
